Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its quarterly earnings results on Tuesday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01), FiscalAI reports.

Zentalis Pharmaceuticals Stock Up 3.4%

Shares of ZNTL stock traded up $0.14 during trading hours on Tuesday, hitting $4.28. 435,618 shares of the company were exchanged, compared to its average volume of 1,959,367. The firm has a market cap of $304.68 million, a PE ratio of -2.25 and a beta of 1.99. Zentalis Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $6.95. The firm has a fifty day moving average of $3.36 and a 200 day moving average of $2.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its position in Zentalis Pharmaceuticals by 8.6% during the fourth quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after buying an additional 14,961 shares in the last quarter. XTX Topco Ltd lifted its position in Zentalis Pharmaceuticals by 5.1% during the fourth quarter. XTX Topco Ltd now owns 576,707 shares of the company’s stock valued at $779,000 after buying an additional 28,078 shares in the last quarter. Quadrature Capital Ltd lifted its position in Zentalis Pharmaceuticals by 126.8% during the fourth quarter. Quadrature Capital Ltd now owns 137,568 shares of the company’s stock valued at $186,000 after buying an additional 76,917 shares in the last quarter. Opaleye Management Inc. lifted its position in Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock valued at $1,891,000 after buying an additional 1,084,356 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its position in Zentalis Pharmaceuticals by 60.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock valued at $108,000 after buying an additional 30,000 shares in the last quarter.

Analyst Ratings Changes

Several research firms have issued reports on ZNTL. Guggenheim raised their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Finally, Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.83.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.